Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Operating Expenses (2022 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Other Operating Expenses for 4 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 611.45% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.4 million through Dec 2025, up 1990.38% year-over-year, with the annual reading at $20.4 million for FY2025, 1990.38% up from the prior year.
  • Other Operating Expenses hit $6.2 million in Q4 2025 for ARS Pharmaceuticals, down from $8.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $11.8 million in Q1 2023 to a low of $112000.0 in Q3 2024.
  • Historically, Other Operating Expenses has averaged $4.3 million across 4 years, with a median of $3.0 million in 2025.
  • Biggest YoY gain for Other Operating Expenses was 7213.39% in 2025; the steepest drop was 611.45% in 2025.
  • Year by year, Other Operating Expenses stood at $774000.0 in 2022, then surged by 1430.23% to $11.8 million in 2023, then tumbled by 92.7% to $865000.0 in 2024, then soared by 611.45% to $6.2 million in 2025.
  • Business Quant data shows Other Operating Expenses for SPRY at $6.2 million in Q4 2025, $8.2 million in Q3 2025, and $5.0 million in Q2 2025.